Uva Ursi Safety: Hydroquinone Risk and Who the Research Raises Concerns For

Green-brown urine after taking uva ursi
Green-brown urine after taking uva ursi

Most readers arrive at a safety page after deciding to take something. If you are reading this with an infection already underway, we are going to reverse the usual order, because the most dangerous thing about uva ursi is not the herb — it is the delay. The Red Flags list comes first for that reason. That list is the part of this page most likely to change what happens to you.

Then come back for the rest, which is about hydroquinone. Uva ursi's proposed active moiety is hydroquinone, a reactive phenol with a substantial toxicology file. That is not a reason for panic — a formal assessment found that short-course, recommended-dose use delivers only a small amount of free hydroquinone — but it is the reason the herb comes with a hard duration ceiling instead of an open-ended “take as needed.” And it is why the safety discussion for bearberry is qualitatively different from, say, chamomile.

One more piece of context that belongs at the top: the randomized placebo-controlled trial of uva ursi in uncomplicated urinary infection was negative. When a remedy has no demonstrated benefit, even a modest risk is a poor trade. See What the Trials Show.


Table of Contents

  1. Red Flags: Signs That Need Medical Care
  2. Hepatotoxicity: The Liver Concern
  3. The Genotoxicity Question, Honestly Stated
  4. Green-Brown Urine: Expected and Harmless
  5. Nausea, Stomach Irritation and the Tannins
  6. Kidney Disease: A Listed Contraindication
  7. Pregnancy, Breastfeeding and Children
  8. Who the Monographs and Research Raise Concerns For
  9. Interactions and Combinations That Raise Concerns
  10. Signs You Have Taken Too Much or Used It Too Long
  11. What Can Be Checked, and When
  12. Evidence Tiers at a Glance
  13. The Bottom Line
  14. Key Research Papers
  15. Connections
  16. Featured Videos

Red Flags: Signs That Need Medical Care

This is the most important section on the page. Each of the following is a sign that doctors treat as needing medical assessment the same day, not after a few more days of tea. In the 2021 German trial that replaced a single-dose antibiotic with uva ursi (398 women), 8 women in the uva ursi group developed a kidney infection (pyelonephritis) against 2 in the fosfomycin group — a difference that did not reach statistical significance (p = 0.067) — and the symptom burden was 136.5% of the antibiotic group’s, so “wait and see” has a recorded cost.

Background on the condition and the escalation: Urinary Tract Infections and Pyelonephritis. A dipstick and urine culture take the guesswork out; see Urinalysis.

Hepatotoxicity: The Liver Concern

Evidence tier: liver harm described in older literature for overdose and long-term use, not supported by case reports; no established pattern of liver injury from short-course bearberry use.

Two things are true at once here, and it is worth holding both.

First, older literature warns that overdose or long-term use can harm the liver. Hydroquinone is metabolised in the liver. The EU assessment report on bearberry leaf (EMA/HMPC/750266/2016) notes that these warnings “are not supported by case reports,” and cites a 13-week study in rats given 25 and 100 mg/kg of hydroquinone a day in which no liver toxicity was observed. The review The toxicology of hydroquinone — relevance to occupational and environmental exposure, Critical Reviews in Toxicology (1999), reports liver adenomas (benign tumours) in mice whose significance it calls uncertain. Because uva ursi's entire proposed action depends on delivering hydroquinone, this is not an incidental contaminant concern. It is a property of the active. PubMed PMID: 10379810

Second, there is no established pattern of liver injury from bearberry leaf taken at monograph doses for a week. The formal assessment specific to bearberry preparations — Risk assessment of free hydroquinone derived from Arctostaphylos uva-ursi folium herbal preparations, International Journal of Toxicology (2013) — concluded that the free hydroquinone actually delivered at recommended doses is small and within accepted safety margins. In numbers: the recommended daily dose (420 mg of hydroquinone derivatives, calculated as arbutin) releases at most 11 µg of free hydroquinone per kg of body weight per day into the urine, against an estimated permitted daily exposure of 100 µg/kg/day; foods eaten regularly over a lifetime give comparable exposure; and the authors found no direct human evidence of free hydroquinone causing convulsions, liver or kidney damage, or tumour promotion. PubMed PMID: 24296864

The reconciliation is straightforward and is the whole reason the duration cap exists: the reassuring conclusion is conditional on the usage pattern. It applies to a week at recommended doses. It does not extend to daily use for a month, to double doses, or to stacked products. If you leave those conditions, you have left the assessment that made the herb look acceptable, and nobody has characterised where you now are.

Signs of liver trouble, whatever the cause, that doctors treat as needing prompt assessment:

Liver disease is not a listed contraindication in the EU monograph; the concern raised in herbal practice rests on the older literature warning above, since hydroquinone is handled by the liver. See Liver Disease. Liver enzymes are a routine blood test if there is any doubt; see Lab Tests.

The Genotoxicity Question, Honestly Stated

Evidence tier: established laboratory genotoxicity of hydroquinone; unresolved relevance at bearberry exposures.

This is the part usually either ignored entirely or inflated into scaremongering. The accurate position sits between.

What is established: hydroquinone is genotoxic in a range of laboratory systems, and long-term rodent bioassays have reported tumours — kidney tubular tumours in male rats and haematological findings in females among them. Regulatory and expert bodies have grappled with what this means for humans; the dedicated evaluation Hydroquinone: an evaluation of the human risks from its carcinogenic and mutagenic properties in Critical Reviews in Toxicology (2007) is the standard reference. PubMed PMID: 18027166

In plain words, that review found: the International Agency for Research on Cancer places hydroquinone in Group 3, “not classifiable” as to cancer in humans; the rat kidney tumours were benign adenomas, seen in male rats and only in areas of an age-related rat kidney disease (chronic progressive nephropathy) that has no human counterpart, so the author judges them “without human consequence”; and most positive DNA-damage results came from injection, while of five studies by mouth only one gave a weak, marginal positive. The EU assessment report on bearberry leaf states that a clear conclusion on genotoxicity “could not be made” and considers the risk from short-term treatment “minimal.”

What is not established:

The honest summary: the genotoxicity question is unresolved, and the monographs manage it by limiting exposure, not by waiting for certainty. That is what the duration rule is: one week per course in the 2018 EU monograph, and no more than five courses a year in the older German Commission E monograph (the current EU monograph sets no yearly limit). It is a precautionary structure built around an open question, even though no one is claiming a week of bearberry tea will harm you.

It is also worth noticing that hydroquinone's regulatory history in cosmetics — where it is used as a skin-lightening agent and has been restricted or banned in over-the-counter products in several jurisdictions — reflects the same underlying concern by a different route. Arbutin itself is used in skin-lightening cosmetics as a blocker of tyrosinase, the enzyme that makes skin pigment, and a 2021 review lists the hydroquinone that may be generated during product use as a safety caution. That parallel does not transfer numbers, but it does confirm that regulators worldwide treat this molecule as one to limit.

Green-Brown Urine: Expected and Harmless

Evidence tier: well-recognised, expected effect.

Uva ursi commonly turns urine a greenish or greenish-brown colour. This is caused by plant pigments and phenolic metabolites being excreted, it is entirely expected, and it is harmless. It resolves within a day or so of stopping.

It is worth knowing in advance for two reasons. First, discovering it unexpectedly at night is alarming, and alarm sends people to emergency departments unnecessarily. Second — and more important — knowing what the expected discolouration looks like helps you notice the unexpected kinds:

In short: green-brown is the herb. Anything else is not; it is a new finding, not part of the “expected.”

Nausea, Stomach Irritation and the Tannins

Evidence tier: well-recognised, common effect.

The commonest complaint from uva ursi has nothing to do with hydroquinone. Bearberry leaf is heavily tannin-laden — often in the region of 15–20% of the dried leaf — and tannins bind proteins, which is what makes the brew so astringent and what irritates the gastric lining.

Typical effects: nausea, stomach ache, a sense of gastric burning, occasionally vomiting. They are dose-related and preparation-related. What reduces them:

A tannin-rich astringent is likely to be poorly tolerated by people with gastritis, peptic ulcer disease, reflux or inflammatory bowel disease.

Kidney Disease: A Listed Contraindication

Evidence tier: pharmacological reasoning; “kidney disorders” are a listed contraindication in the EU monograph.

Uva ursi is contraindicated in kidney disease and reduced kidney function, and the reasoning is unusually clean. The herb's entire mode of action depends on the kidney filtering hydroquinone conjugates into urine. That means:

  1. Impaired clearance changes the exposure. If the kidney is not clearing conjugates efficiently, they persist systemically for longer — the opposite of the brief-exposure pattern on which the herb's safety argument depends.
  2. The kidney is itself a target organ in hydroquinone bioassays. Rodent studies reported renal tubular findings. Adding a hydroquinone-yielding herb to an already compromised kidney is the wrong direction of travel.
  3. Urinary infection in someone with kidney disease is not an uncomplicated infection. It needs proper diagnosis and treatment regardless of what herbs are available.

The same logic applies to anyone taking other nephrotoxic agents — regular high-dose nonsteroidal anti-inflammatory drugs (NSAIDs) being the commonest in ordinary life. See Kidney Disease and Kidney Function Tests. If you do not know your kidney function, a basic blood test with creatinine and estimated glomerular filtration rate (eGFR) gives it.

A note on kidney stones: uva ursi's nineteenth-century use for “gravel” is traditional use only and is a poor idea in practice, both because it has no supporting evidence and because the alkalinising advice traditionally paired with the herb changes stone chemistry in ways that help some stone types and worsen others. See Kidney Stones.

Pregnancy, Breastfeeding and Children

Evidence tier: not recommended in the EU monograph, because safety has not been established.

Who the Monographs and Research Raise Concerns For

Collected in one place: the groups for whom the EU monograph lists a contraindication or does not recommend use, and those for whom the research and herbal practice raise a concern.

Interactions and Combinations That Raise Concerns

Formal drug-interaction studies on bearberry are sparse, so most of what follows is pharmacological caution rather than documented interaction. It is stated as such.

Abnormal liver tests, greenish urine or gastric symptoms are much easier for a clinician or pharmacist to interpret when they know which herbal products are being taken.

Signs You Have Taken Too Much or Used It Too Long

These signs are described with too much uva ursi or too long a course:

If a child has swallowed a quantity of uva ursi, or if an adult has taken a large amount, a poisons information service or emergency service can advise before any symptoms appear.

What Can Be Checked, and When

Short-course use in a healthy adult does not routinely need monitoring. Where a check is worthwhile:

Evidence Tiers at a Glance

  1. Randomized clinical trial — negative. Uva ursi did not shorten symptoms of uncomplicated urinary infection versus placebo, which is the context for every risk on this page. In the ATAFUTI trial (382 women), the difference in frequency symptoms on days 2–4 was −0.06 (p = 0.661), and no upper urinary tract infections were recorded.
  2. Randomized clinical trial — unfavourable. Replacing single-dose fosfomycin with uva ursi (398 women) cut antibiotic courses by 63.6% but gave a symptom burden 136.5% of the antibiotic group’s, failing non-inferiority, and 8 cases of pyelonephritis against 2 (p = 0.067, not statistically significant).
  3. Established toxicology. Liver harm with overdose or long-term use is described in older literature but not supported by case reports, and a 13-week rat study found none; hydroquinone is genotoxic in some laboratory systems, mostly when injected, and caused benign kidney tumours in male rats.
  4. Formal risk assessment. Free hydroquinone delivered by standard bearberry preparations at recommended doses for short periods is small and within accepted margins (at most 11 µg/kg a day against a permitted 100 µg/kg) — conditional on dose and duration.
  5. Well-recognised, expected effect. Greenish-brown urine; nausea and gastric irritation from tannins.
  6. EU monograph. Contraindicated in kidney disorders and hypersensitivity; not recommended in pregnancy, breastfeeding, under 18 years or in men; liver disease is a concern raised in herbal practice, not a listed contraindication.
  7. Pharmacological caution, not documented interaction. Nephrotoxic and hepatotoxic co-medication; alkalinising and acidifying agents; lithium; diuretics; iron.
  8. Traditional use only. The alkaline-urine requirement; use for “gravel”; astringent soothing of the bladder.
  9. Not supported. That short-course bearberry use causes cancer — no such evidence exists; that hydroquinone exposure can be dismissed at any duration — equally unsupported; that a cold preparation reduces hydroquinone exposure.

The Bottom Line

Uva ursi occupies an unusual and uncomfortable position. Its mechanism is genuinely interesting, its pharmacokinetics in humans are properly documented, and unlike most herbs it was actually put through a randomized placebo-controlled trial. The trial said no. And its proposed active moiety is a compound that regulators limit rather than encourage.

Put together:

  1. No demonstrated benefit in the condition it is sold for.
  2. A documented cost when it displaces treatment — a higher symptom burden, and 8 kidney infections against 2 in the fosfomycin trial (not statistically significant).
  3. A hydroquinone ceiling — one week per course, and five courses a year in Commission E — that rules out the long or repeated use people most want.
  4. A group of people for whom the EU monograph lists a contraindication or does not recommend it — kidney disorders; pregnancy, breastfeeding, under-18s and men — plus liver disease as a concern raised in herbal practice.
  5. A red-flag list that matters far more than any of the above, because an escalating urinary infection is a real and reversible danger.

If someone still chooses to use it for a short course with none of the contraindications, the harm from one week at monograph doses appears to be small. But that is a very different sentence from “it works,” and this page is written so you can tell the two apart.

Key Research Papers

Entries for a single paper end with their PubMed PMID link; the last two entries are PubMed topic searches.

  1. de Arriba SG, Naser B, Nolte KU. Risk assessment of free hydroquinone derived from Arctostaphylos Uva-ursi folium herbal preparations. International Journal of Toxicology, 2013;32(6):442-53. The assessment underpinning short-course use. PubMed PMID: 24296864
  2. McGregor D. Hydroquinone: an evaluation of the human risks from its carcinogenic and mutagenic properties. Critical Reviews in Toxicology, 2007;37(10):887-914. The genotoxicity question examined directly. PubMed PMID: 18027166
  3. DeCaprio AP. The toxicology of hydroquinone — relevance to occupational and environmental exposure. Critical Reviews in Toxicology, 1999;29(3):283-330. Liver and kidney toxicity background. PubMed PMID: 10379810
  4. Moore M, Trill J, Simpson C, et al. Uva-ursi extract and ibuprofen as alternative treatments for uncomplicated urinary tract infection in women (ATAFUTI): a factorial randomized trial. Clinical Microbiology and Infection, 2019;25(8):973-980. The negative placebo-controlled trial. PubMed PMID: 30685500
  5. Gágyor I, Hummers E, Schmiemann G, Friede T, Pfeiffer S, Afshar K, Bleidorn J. Herbal treatment with uva ursi extract versus fosfomycin in women with uncomplicated urinary tract infection in primary care: a randomized controlled trial. Clinical Microbiology and Infection, 2021;27(10):1441-1447. Higher symptom burden and numerically more pyelonephritis in the herbal arm. PubMed PMID: 34111592
  6. Schindler G, Patzak U, Brinkhaus B, et al. Urinary excretion and metabolism of arbutin after oral administration of Arctostaphylos uvae ursi extract as film-coated tablets and aqueous solution in healthy humans. Journal of Clinical Pharmacology, 2002;42(8):920-7. Confirms systemic hydroquinone conjugate exposure. PubMed PMID: 12162475
  7. Quintus J, Kovar KA, Link P, Hamacher H. Urinary excretion of arbutin metabolites after oral administration of bearberry leaf extracts. Planta Medica, 2005;71(2):147-52. Independent pharmacokinetic confirmation. PubMed PMID: 15729623
  8. Siegers C, Bodinet C, Ali SS, Siegers CP. Bacterial deconjugation of arbutin by Escherichia coli. Phytomedicine, 2003;10 Suppl 4:58-60. The local-activation hypothesis — and why the active moiety is hydroquinone. PubMed PMID: 12807345
  9. Schmiemann G, Kniehl E, Gebhardt K, Matejczyk MM, Hummers-Pradier E. The diagnosis of urinary tract infection: a systematic review. Deutsches Ärzteblatt International, 2010;107(21):361-7. Why symptoms alone misclassify a meaningful share of episodes. PubMed PMID: 20539810
  10. Hooton TM. Clinical practice. Uncomplicated urinary tract infection. New England Journal of Medicine, 2012;366(11):1028-37. Where “uncomplicated” stops applying — the clinical basis of the red-flag list. PubMed PMID: 22417256
  11. Yarnell E. Botanical medicines for the urinary tract. World Journal of Urology, 2002;20(5):285-93. Review of urinary herbs and their cautions. PubMed PMID: 12522584
  12. Boo YC. Arbutin as a Skin Depigmenting Agent with Antimelanogenic and Antioxidant Properties. Antioxidants (Basel), 2021;10(7):1129. How arbutin lightens skin, and the hydroquinone safety caution. PubMed PMID: 34356362
  13. Wang L, Del Priore LV. Bull's-eye maculopathy secondary to herbal toxicity from uva ursi. American Journal of Ophthalmology, 2004;137(6):1135-7. Retinal damage after 3 years of use. PubMed PMID: 15183807
  14. Screening and treatment of urinary infection and asymptomatic bacteriuria in pregnancy — why pregnancy is the clearest case against self-treating. PubMed search
  15. Regulatory restriction of hydroquinone in topical skin-lightening products — the same molecule limited by a different route. PubMed search

External Resources

  1. European Medicines Agency — the bearberry-leaf monograph and assessment report behind the contraindications and duration limit.
  2. EU herbal monograph on bearberry leaf (January 2018) — indication, one-week limit, contraindications and who it is not recommended for.
  3. EU assessment report on bearberry leaf — the toxicology, overdose literature, maculopathy case and the older Commission E limits.
  4. US National Toxicology Program — toxicology and carcinogenesis evaluations of hydroquinone.
  5. PubMed — index behind every citation above.
  6. NCCIH — plain-language herb safety summaries.
  7. NHS — when urinary symptoms need urgent assessment.
  8. CDC — antibiotic use, resistance and urinary infection guidance.

Back to Table of Contents

Connections


Safety note. This page is general health education, not medical advice, and it cannot diagnose you. Uva ursi's active moiety is hydroquinone; older literature warns of liver harm with overdose or long-term use (not supported by case reports), and its genotoxicity is unresolved. The 2018 EU monograph limits use to one week, and the older Commission E monograph to no more than five courses a year. The EU monograph lists kidney disorders as a contraindication and does not recommend use in pregnancy, breastfeeding, under 18 years or in men; liver disease is a concern raised in herbal practice. Fever, flank or back pain, nausea or vomiting, blood in the urine, urinary symptoms in pregnancy, in a man or in a child, recurrent infection, or no clear improvement within 48 hours are signs doctors treat as needing prompt care, and feeling very unwell, confused or breathless as urgent. Yellowing of the skin or eyes, unusual fatigue, or reduced urine output are signs of possible liver or kidney involvement that hospitals treat as urgent. Clinicians and pharmacists can interpret symptoms more easily when they know which herbal products are being taken.

Back to Table of Contents